Gilead Sciences acquired Myogen Inc. for $52.50 per share (~$2.5 billion) in an all-cash tender offer, gaining ambrisentan (Letairis), an oral endothelin receptor antagonist for pulmonary arterial hypertension, and darusentan for resistant hypertension. The deal marked Gilead's entry into cardiovascular/pulmonary medicine.